Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Psoriatic arthritis
•
General Rheumatology
•
Dermatology
Would you continue TNF-inhibitor in a patient with psoriatic arthritis who has had multiple nonmelanoma skin cancers requiring Mohs surgery?
Related Questions
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
How do you approach managing nausea and GI side effects when initiating methotrexate?
Would you switch azathioprine to a different immunosuppressant if a controlled patient with SLE develops melanoma and/or non-melanoma skin cancer?
In a patient with psoriatic arthritis and recurrent pericarditis, would you combine abatacept or other biologics with rilonacept?
What circumstances would drive you to consider using an oral IL-23 inhibitor over parenteral options for the management of psoriasis and/or psoriatic arthritis?
How would you approach management of an elderly patient with known mantle cell lymphoma and new diagnosis of cryoglobulinemic vasculitis with mild skin involvement, fatigue, arthralgias but no other major organ involvement?
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
How do you counsel patients on the risks and benefits of an IL-23 agent versus an IL-17A or IL-17A/F agent?
How do you approach management of patients with psoriatic arthritis who have significant improvement in skin disease, but ongoing inflammatory arthritis despite multiple DMARDs and/or biologics?
